NorthWest Biotherapeutics Inc (NWBO)

[JerryCampbell]

1) Obtaining a GBM population that closely matches nwbo's screening criteria in terms of disease state, age, operable, health, etc. The control group treatment must closely match. Doubt they can consider treatment patients from other trials.

2) How cooperative are other firms at providing data? How much are they allowed to share under agreements with trial patients? Have they continued to follow patients after the trial?

3) Can't use data that is too old because newer patients might benefit from newer surgical techniques. Ex: 5-ala allowing a higher percentage of total resection.

4) Did other trials record all the data that nwbo might want/need for its analysis? Do they need to re-read old scans?


There's probably lots more.